Treatment Of Candida Vaginitis Research Articles

Evaluation of the Therapeutic Effect of 15 ppm Silver Nanoparticle Spray Compared to Clotrimazole 1% on Candida Vaginitis: A Randomized Controlled Clinical Trial.

In vitro and in vivo researches have shown that silver nanoparticles have more antimicrobial properties with a lower concentration than antifungal agents against candida vaginitis. Therefore, this study evaluated the therapeutic effect of silver nanoparticles (Nivasha spray15ppm) compared to clotrimazole 1% vaginal cream on candida vaginitis. In this clinical trial study, 110 women with confirmed candida vaginitis randomly were divided into test (n=58) and control (n=52) groups. Silver nanoparticles spray with an applicator (Nivasha 15 ppm), and clotrimazole 1% were administered to test and control groups, respectively. Then, within ten days, post-intervention checkup and patient self-reported for treatment results were recorded in checklists and the data were analyzed statistically. The improvement rate in test group (98.0%) was 1.44 times higher than in control (67.9%). Moreover, disease symptoms after the intervention (including unusual secretions, itching and burning, redness) in test group were significantly less than in the control, but there was no significant difference in the ratio of edema in two groups (p=0.071). Furthermore, the average recovery time (days) of all symptoms in test group was lower than control (p<0.05). Finally, the rate of patients' satisfaction with the treatment process in the test group (76.9%) was more than control (46.6%) (p=0.004). Nivasha spray had more effectiveness compared to the clotrimazole 1%. Therefore, it can be used as an alternative drug in the treatment of Candida vaginitis.

Thermosensitive hydrogels as a controlled release system for alkannin to improve localized treatment of Candida vaginitis after external beam radiotherapy in vitro and in vivo.

External beam radiotherapy increases the risk of Candida vaginitis in cervical cancer patients, which brings a lot of insufferable influence to their life. Here, we explored the efficacy of alkannin in the treatment of Candida vaginitis after external beam radiotherapy. We exploit thermosensitive hydrogel-mediated alkannin as the topical formulation in a rat model established in our work. Periodic acid-Schiff of vaginas indicated little Candida albicans adhered to the vaginal tissue in treatment group. Additionally, hematoxylin and eosin stain revealed that inflammatory response of high dose alkannin was reduced. Above all, the animal model was first established in our work for the clinical desire. Our results suggested the promising application of alkannin for the disease with satisfying fungicidal activity and anti-inflammatory activity.

Meta analysis of clinical efficacy of fluconazole combined with clotrimazole in the treatment of candida vaginitis

Objective To explore the clinical efficacy of oral fluconazole combined with clotrimazole vaginal administration in the treatment of candida vaginitis by meta analysis. Methods Fluconazole combined with clotrimazole was selected as experiment group and clotrimazole alone was selected as control group. The randomized controlled trials(RCTs) were retrieved from PubMed, Cochrane library, Embase, China Notional Knowledge infrastructure(CNKI), WangFang and VIP database and references listed in all studies. RCTs meeting inclusive studies were included, the data were extracted, the quality was evaluated and cross-checked by two reviews independently according to Cochrane Handbook for Systematic Reviews of Interventions and then Meta-analysis was conducted using Stata14.0 software. Results A total of 15 studies and 1 792 patients were included.The experiment group had a higher overall efficiency(experiment group in 96.13% and control group in 83.8%), the difference was statistically significant (RR=1.13, 95%CI 1.08~1.18, P<0.001). The recurrence rate after treatment(experiment group in 6.46% and control group in 20.74%) had statistically significant difference between the two groups (RR=0.31, 95%CI 0.21~0.46, P<0.001). Conclusion Meta analysis showed that oral fluconazole combined with clotrimazole vaginal administration has a better clinical efficacy. Key words: Candidiasis, vulvovaginal; Randomized controlled trial; Meta-analysis; Fluconazole; Clotrimazole; Effective rate; Relapse rate

Comparative Investigation of the Sensitivity of Candida Fungi Isolated From Vulvovaginal Candidiasis to Nystatin and Teucrium polium Smoke Product

Objectives: The present study aimed to compare the antifungal activities of Teucrium Polium smoke product and nystatin in the treatment of Candida vaginitis in vitro. Materials and Methods: In this quasi-experimental study, 105 subjects were diagnosed with Candida vaginitis. The data were collected through a collection form and the species were isolated by the germ tube, as well as CHROMagar chromogenic and chlamydospore formation tests. Results: Based on the results of the germ tube, chlamydospore formation, and CHROMagar tests, 70.5%, 23.8%, and 66.6% of the species were Candida albicans, respectively. In addition, 99% of the samples were sensitive to nystatin. A significant relationship was also observed between the antifungal drug and the type of organism (P&lt;0.02). Finally, all the 15 standard clinical samples were sensitive to T. polium smoke. Conclusions: In general, the results confirmed the antifungal effects of T. polium and nystatin on the species isolated from 10 clinical samples obtained from Candida vaginitis as well as on five standard strains.

Efficacy of nystatin vaginal effervescent tablets and nifuratel tablet combined with recombinant human interferon alpha 2b suppository in the treatment of candida vaginitis

Objective To explore the efficacy of nystatin vaginal effervescent tablets, nifuratel tablet combined with recombinant human interferon alpha 2b suppository in the treatment of candida vaginitis. Methods 124 patients with candida vaginitis were selected as the research subjects.The patients were randomly divided into two groups according to different treatment.The control group was treated with nystatin vaginal effervescent tablets + nifuratel tablet, the study group was given recombinant human interferon alpha 2b suppository on the basis of the control group.The symptoms, clinical curative effect, quality of life score, adverse reaction rate were observed and compared in the two groups. Results There were no statistically significant differences between the two groups in symptom and physical signs before treatment(all P>0.05). After treatment, the vulvar itching, burning pain, abnormal leucorrhea, redness symptoms and signs of the study group were (0.95±0.44)points, (1.02±0.51)points, (1.13±0.62)points, (1.09±0.56)points, which were significantly lower than those of the control group[(1.42±0.98)points, (1.28±1.02)points, (1.38±1.17)points, (1.37±1.12)points, t=2.529, 2.512, 2.505, 2.618, all P<0.05]. The total effective rate of the study group was 95.2%, which was significantly higher than 74.2% of the control group (Z=-2.839, P<0.05). After treatment, the quality of life scores of physiological function, bodily pain, mental health, emotional function and social function in the study group were (80.16±9.23)points, (84.22±9.95)points, (87.49±10.46)points, (89.27±12.35)points, (88.21±11.74)points, which were significantly higher than those in the control group[(67.58±5.34)points, (71.49±7.28)points, (73.52±7.61)points, (76.83±8.32)points, (75.51±8.16) points, t=9.728, 8.577, 9.036, 7.039, 7.537, all P<0.05]. The incidence rate of adverse reactions of the study group was significantly lower than that of the control group(χ2=10.978, P<0.05). Conclusion Nystatin vaginal effervescent tablets, nifuratel tablet combined with recombinant human interferon alpha 2b suppository in the treatment of candida vaginitis can significantly improve clinical symptoms, improve the therapeutic effect, and improve the quality of life of patients with significant clinical value, it is worthy of reference. Key words: Candidiasis, vulvovaginal; Nystatin; Nifuratel; Interferon alpha 2b

P924 Complementary treatment for candida vaginitis: a comparison study of vinegar and soda solution baths in the treatment of candida vaginitis

P924 Complementary treatment for candida vaginitis: a comparison study of vinegar and soda solution baths in the treatment of candida vaginitis

The treatment of Candida vaginitis and vulvitis

Vulvovaginitis may have an infectious cause, a non-infectious cause or a combination of both. A

Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges.

The availability of several potent antifungal agents, systemic or topical, over the counter or prescription would suggest that therapeutic needs for Candida vaginitis are minimal or absent. Unfortunately, unmet needs still exist. Moreover, the pharmaceutical industry has abandoned Candida vaginitis and no new agents or studies are imminent. Perhaps the most important advance in the last decade has been the recognition that therapy must be individualized and that not all forms of Candida vaginitis are equal. A critical factor is duration of therapy and the need for maintenance therapy in recurrent candidiasis. In addition, serious deficiencies exist in the therapy of C. glabrata vaginitis, an emerging problem. Azole therapy for C. glabrata frequently fails, depleting the therapeutic armamentarium of successful options. Additional therapeutic challenges remain for women who can be easily controlled but not cured with intensive azole therapy in spite of absence of in vitro antifungal resistance. Any advance in non-drug related therapy will require a better understanding of the immunopathogenesis of VVC and effective naturally occurring host protective mechanisms. Copyright 1999 Harcourt Publishers Ltd.

Seven-Day Clotrimazole Therapy for Vulvovaginal Candidiasis

There were 150 patients with mycologically proven vulvovaginal candidiasis in a randomized, non-cross-over study which compared seven-and 14-day treatment courses of clotrimazole vaginal tablets (Gyne-Lotrimin) with a 14-day treatment course of miconazole nitrate 2% vaginal cream (Monistat). Adequate data for analyses were obtained for 117 patients. When patients were reexamined four or more weeks after completion of therapy, success rates, based on clinical and mycologic criteria, were: 88% for patients treated with clotrimazole for seven days, 84% for clotrimazole 14-day treatment, and 78% for miconazole nitrate 14-day treatment. There were no drug-related adverse reactions. Thus a seven-day course of therapy with clotrimazole is effective as is a 14-day course of either clotrimazole or miconazole nitrate 2% for the treatment of Candida vaginitis. Statistical analysis revealed no significant differences among the clotrimazole seven-and 14-day treatment groups and the miconazole nitrate 14-day treatment group. The shorter period of administration required for this new antifungal agent should result in better patient compliance and an improved success rate in the rate in the treatment of this frequently encountered infection.